ReviewCurrent urology reports2026
Minimally Invasive Surgery in Solitary Kidneys with Renal Tumors: A Surgical Evolution.
Review in Current urology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThis review aims to critically evaluate the evolving role of minimally invasive surgery (MIS) in the nephron-sparing management of renal tumors in patients with a solitary kidney. We sought to assess current evidence regarding surgical approaches, ischemia strategies, oncologic and functional outcomes, and to identify key determinants guiding surgical decision-making in this high-risk population. RECENT
findingsRecent literature exhibits a progressive shift toward minimally invasive approaches, without compromising oncologic or long-term functional outcomes. Accumulating evidence highlights preserved renal parenchymal volume and baseline renal function as the primary predictors of postoperative renal recovery, whereas ischemia type and time mainly affect early postoperative function. Advanced technologies, including 3D modeling, may further optimize selective clamping and perioperative outcomes in selected cases. Partial nephrectomy remains the mainstay of treatment for renal tumors in solitary kidneys. Surgical approach selection should be individualized, driven by tumor complexity and renal function rather than technique alone. Referral to high-volume centers and continued refinement of MIS are essential to optimize outcomes and guide future research in this challenging clinical setting.
Indexed as
Identifiers
41706412What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.